Why the study?
Does a 30-day drug-free period identify a subgroup of schizophrenic patients who improve without standard neuroleptic doses?
Does a 30-day drug-free period identify a subgroup of schizophrenic patients who improve without standard neuroleptic doses?
A subgroup of schizophrenic patients may improve during a drug-free period and subsequently require lower than standard doses of neuroleptics.
In a sample of 22 psychotic schizophrenic patients, eight improved substantially during a 30-day drug-free period. The drug-free improver group differed from the nonimprover group in demonstrating a later age of onset, briefer psychotic episodes, shorter hospitalizations, and better prognostic scores on the Phillips Scale, Strauss-Carpenter Modified Prognostic Scale, and the Vaillant Scale. After drug withdrawal, drug-free improvers frequently demonstrated further improvement when treated with doses of neuroleptic drugs that were substantially lower than the clinically recommended doses. The authors raise the question as to whether the drug-free improvers may represent a subgroup of schizophrenic patients who are being overtreated presently by standard neuroleptic practice.
No takes yet. Share an insight, caveat, or question.
Stephen R. Marder (1979) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: